Pancreatic Cancer Research

ResearcherNagoya UniversityActive in the last 2 years

Shunsuke Onoe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0498-5586; OpenAlex author ID A5011048888. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 5 papers · 2024: 1 paper · 2025: 2 papers

Papers 10

  1. Close correlation between patients' positive mood and postoperative complication burden in hepato-biliary-pancreatic cancer: a prospective comparative cohort t… Co-author DOI 10.1016/j.hpb.2025.07.015↗
  2. FAM111B Suppression Enhances Sensitivity to Gemcitabine in Pancreatic Cancer Through Intracellular pH Regulation. Co-author DOI 10.1111/cas.70212↗
  3. Trefoil factor 1 suppresses stemness and enhances chemosensitivity of pancreatic cancer. Co-author DOI 10.1002/cam4.7395↗
  4. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan P… Co-author DOI 10.1007/s00535-023-01988-7↗
  5. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  6. Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer. Co-author DOI 10.1007/s10147-023-02321-1↗
  7. Antitumor Effects of Deep Ultraviolet Irradiation for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16198↗
  8. Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16245↗
  9. Tumor marker recovery rather than major pathological response is a preferable prognostic factor in patients with pancreatic ductal adenocarcinoma with preopera… Co-author DOI 10.1002/jhbp.748↗
  10. Prognostic impact of splenic artery invasion for pancreatic cancer of the body and tail. Last author DOI 10.1016/j.ijsu.2016.09.076↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junpei Yamaguchi · 7 shared papers, 2020–2025 · strength 1.27
  2. Tomoki Ebata · 6 shared papers, 2023–2025 · strength 1.16
  3. Yukihiro Yokoyama · 6 shared papers, 2020–2025 · strength 1.02
  4. Masaki Sunagawa · 5 shared papers, 2023–2025 · strength 0.99
  5. Toshio Kokuryo · 4 shared papers, 2023–2025 · strength 0.76
  6. Shoji Kawakatsu · 3 shared papers, 2023–2025 · strength 0.61
  7. Taisuke Baba · 2 shared papers, 2023–2025 · strength 0.40
  8. Kimitoshi Yamazaki · 2 shared papers, 2023 · strength 0.31
  9. Masato Nagino · 2 shared papers, 2023 · strength 0.31
  10. Yasuhiro Kodera · 2 shared papers, 2020–2023 · strength 0.28
  11. Motonobu Nishimura · 1 shared paper, 2025 · strength 0.25
  12. Hiroki Nakajima · 1 shared paper, 2023 · strength 0.17
  13. Mikiko Kano Takebayashi · 1 shared paper, 2023 · strength 0.15
  14. Sohei Satoi · 1 shared paper, 2023 · strength 0.14
  15. Tsuyoshi Hayashi · 1 shared paper, 2023 · strength 0.14
  16. Hidetoshi Eguchi · 1 shared paper, 2023 · strength 0.14
  17. Yoshito Tomimaru · 1 shared paper, 2023 · strength 0.14
  18. Yasutoshi Kimura · 1 shared paper, 2023 · strength 0.14
  19. Daisuke Hashimoto · 1 shared paper, 2023 · strength 0.14
  20. Yoshifumi Takeyama · 1 shared paper, 2023 · strength 0.14
  21. Akihiro Ohba · 1 shared paper, 2023 · strength 0.14
  22. Yosuke Inoue · 1 shared paper, 2023 · strength 0.14
  23. Kenichiro Uemura · 1 shared paper, 2023 · strength 0.14
  24. Yuichi Nagakawa · 1 shared paper, 2023 · strength 0.14
  25. Michiaki Unno · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.